Brain research has high returns but Europe is lagging behind

被引:4
作者
Sobocki, P.
Olesen, J.
Jonsson, B.
机构
[1] Karolinska Inst, Stockholm, Sweden
[2] Univ Copenhagen, Glostrup Hosp, Dept Neurol, Copenhagen, Denmark
[3] Stockholm Sch Econ, S-11383 Stockholm, Sweden
关键词
brain disorders; brain research; cost; cost-benefit; Europe funding;
D O I
10.1111/j.1468-1331.2007.01816.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We have shown that brain disorders cost Europe almost e400 billion annually, whereas the funding for brain research is only 1% of that amount. There is a growing understanding of the ability of research to improve prevention, treatment and rehabilitation of brain disease and thereby reduce the burden on the affected individuals and on society. New studies have shown that brain research is highly profitable, with conservatively measured annual returns of 50% or more. However, funding of brain research in Europe, particularly public funding, is lagging behind when compared with the US. We argue that increased public investment in brain research in Europe is critical and will most likely be highly cost-effective to European society. If Europe wants to remain competitive in the field of brain research, public investments must be increased several fold over today's investment.
引用
收藏
页码:708 / 710
页数:3
相关论文
共 14 条
[1]   Cost of disorders of the brain in Europe [J].
Andlin-Sobocki, P ;
Jönsson, B ;
Wittchen, HU ;
Olesen, J .
EUROPEAN JOURNAL OF NEUROLOGY, 2005, 12 :1-+
[2]  
[Anonymous], 2003, MEASURING GAINS MED
[3]   Substantial returns to health-care spending: But do we spend too little or too much? [J].
Buxton, MJ .
VALUE IN HEALTH, 2006, 9 (03) :144-145
[4]   TGhe value of medical spending in the United States, 1960-2000 [J].
Cutler, David M. ;
Rosen, Allison B. ;
Vijan, Sandeep .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (09) :920-927
[5]  
CUTLER DM, 2001, HEALTH AFFAIR, V20, P11
[6]   Use of cost-effectiveness analysis in health-care resource allocation decision-making:: How are cost-effectiveness thresholds expected to emerge? [J].
Eichler, HG ;
Kong, SX ;
Gerth, WC ;
Mavros, P ;
Jönsson, B .
VALUE IN HEALTH, 2004, 7 (05) :518-528
[7]  
Gold MR, 1996, COST EFFECTIVENESS H
[8]   Effect of a US National Institutes of Health programme of clinical trials on public health and costs [J].
Johnston, SC ;
Rootenberg, JD ;
Katrak, S ;
Smith, WS ;
Elkins, JS .
LANCET, 2006, 367 (9519) :1319-1327
[9]   The return on investment in health care: From 1980 to 2000 [J].
Luce, BR ;
Mauskopf, J ;
Sloan, FA ;
Ostermann, J ;
Paramore, LC .
VALUE IN HEALTH, 2006, 9 (03) :146-156
[10]   The burden of brain diseases in Europe [J].
Olesen, J ;
Leonardi, M .
EUROPEAN JOURNAL OF NEUROLOGY, 2003, 10 (05) :471-477